Zevra Therapeutics

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

zvra

Biotech

News

Health Care

General

ZVRA

The FDA has approved Zevra Therapeutics&#39; Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic Metabolic Diseases Advisory Committee.

Zevra Therapeutics&#39; Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease

Nikola Motor

Intraday Update

Markets

Movers

Trading Ideas

ALTS

ALZN

APDN

APPS

CING

CLOV

FFIE

FHTX

FUBO

GNLN

GOVX

IBRX

INZY

LLAP

LQDA

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NKLA

SEEL

SIDU

SOND

TELO

TGTX

TNXP

TOVX

VALN

VRAX

XPER

Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

earnings

Earnings

After-Hours Center

Zevra Therapeutics reported its second-quarter financial results Tuesday. Here&#39;s a look at the details.

Zevra Therapeutics Mixed Q2 Results: Details

Zevra Therapeutics Inc

Dividends

L3Harris Announces Quarterly Dividend Increase From $1.16 To $1.20 Per Share

Citigroup analyst James Hardiman maintains Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Buy and raises the price target from $32 to $34.

Price Target

Analyst Ratings

NCLH

Citigroup Maintains Buy on Norwegian Cruise Line, Raises Price Target to $34

Investors with a lot of money to spend have taken a bearish stance on Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with ADSK, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 23 options trades for Autodesk.
This isn't normal.
The overall sentiment of these big-money traders is split between 17% bullish and 30%, bearish.
Out of all of the options we uncovered, 22 are puts, for a total amount of $1,177,504, and there was 1 call, for a total amount of $49,147.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $250.0 to $290.0 for Autodesk over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Autodesk options trades today is 513.56 with a total volume of 7,395.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Autodesk's big money trades within a strike price range of $250.0 to $290.0 over the last 30 days.
<h3>Autodesk 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740770165_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$19.3</td>
<td>$17.4</td>
<td>$17.3</td>
<td>$290.00</td>
<td>$173.0K</td>
<td>820</td>
<td align="right">112</td>
</tr>
<tr>
<td>ADSK</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$19.9</td>
<td>$18.2</td>
<td>$19.07</td>
<td>$290.00</td>
<td>$76.2K</td>
<td>820</td>
<td align="right">152</td>
</tr>
<tr>
<td>ADSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$1.8</td>
<td>$1.2</td>
<td>$1.67</td>
<td>$270.00</td>
<td>$70.8K</td>
<td>1.2K</td>
<td align="right">319</td>
</tr>
<tr>
<td>ADSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$18.2</td>
<td>$17.6</td>
<td>$18.1</td>
<td>$270.00</td>
<td>$63.3K</td>
<td>64</td>
<td align="right">35</td>
</tr>
<tr>
<td>ADSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$11.4</td>
<td>$9.3</td>
<td>$10.35</td>
<td>$277.50</td>
<td>$55.2K</td>
<td>1.0K</td>
<td align="right">654</td>
</tr>
</tbody>
</table>

<h3>About Autodesk</h3>
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction; product design and manufacturing; and media and entertainment. Autodesk software enables design, modeling, and rendering needs of these industries. The company has over 4 million paid subscribers across 180 countries.
In light of the recent options history for Autodesk, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Autodesk</h3>
<ul>
<li>With a trading volume of 2,846,140, the price of ADSK is down by -4.72%, reaching $269.01.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 101 days from now.</li>
</ul>
<h3>Expert Opinions on Autodesk</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $345.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Autodesk, which currently sits at a price target of $350. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Neutral rating for Autodesk, targeting a price of $335. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Autodesk with a target price of $345. 
&#x2A; Maintaining their stance, an analyst from Macquarie continues to hold a Outperform rating for Autodesk, targeting a price of $360. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Autodesk, targeting a price of $336. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Autodesk with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

ADSK

Autodesk's Options: A Look at What the Big Money is Thinking

Financial giants have made a conspicuous bearish move on Rigetti Computing. Our analysis of options history for Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) revealed 21 unusual trades.
Delving into the details, we found 28% of traders were bullish, while 52% showed bearish tendencies. Out of all the trades we spotted, 15 were puts, with a value of $740,047, and 6 were calls, valued at $236,300.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $37.0 for Rigetti Computing over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Rigetti Computing options trades today is 1292.86 with a total volume of 17,817.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Rigetti Computing's big money trades within a strike price range of $5.0 to $37.0 over the last 30 days.
<h3>Rigetti Computing Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740770160_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RGTI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.6</td>
<td>$2.55</td>
<td>$2.55</td>
<td>$10.00</td>
<td>$238.6K</td>
<td align="right">133</td>
<td>1.5K</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$3.1</td>
<td>$2.9</td>
<td>$3.0</td>
<td>$8.00</td>
<td>$90.0K</td>
<td align="right">503</td>
<td>305</td>
</tr>
<tr>
<td>RGTI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.55</td>
<td>$2.5</td>
<td>$2.55</td>
<td>$10.00</td>
<td>$51.0K</td>
<td align="right">133</td>
<td>615</td>
</tr>
<tr>
<td>RGTI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.55</td>
<td>$2.5</td>
<td>$2.55</td>
<td>$10.00</td>
<td>$50.9K</td>
<td align="right">133</td>
<td>415</td>
</tr>
<tr>
<td>RGTI</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$2.65</td>
<td>$2.55</td>
<td>$2.6</td>
<td>$10.00</td>
<td>$43.6K</td>
<td align="right">133</td>
<td>2.3K</td>
</tr>
</tbody>
</table>

<h3>About Rigetti Computing</h3>
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, it derives a majority of its revenue from the United States.
In light of the recent options history for Rigetti Computing, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Rigetti Computing</h3>
<ul>
<li>Currently trading with a volume of 47,052,075, the RGTI's price is up by 3.66%, now at $8.32. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 5 days.</li>
</ul>
<h3>Expert Opinions on Rigetti Computing</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $14.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Benchmark persists with their Buy rating on Rigetti Computing, maintaining a target price of $14. 
&#x2A; Consistent in their evaluation, an analyst from B. Riley Securities keeps a Buy rating on Rigetti Computing with a target price of $15. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Rigetti Computing options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

RGTI

What the Options Market Tells Us About Rigetti Computing

Deep-pocketed investors have adopted a bullish approach towards Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CART usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Maplebear. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 77% leaning bullish and 11% bearish. Among these notable options, 4 are puts, totaling $216,873, and 5 are calls, amounting to $195,760.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $36.0 to $42.0 for Maplebear during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Maplebear options trades today is 430.14 with a total volume of 2,238.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Maplebear's big money trades within a strike price range of $36.0 to $42.0 over the last 30 days.
<h3>Maplebear Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740770155_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CART</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.4</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$42.00</td>
<td>$78.5K</td>
<td>471</td>
<td>1</td>
</tr>
<tr>
<td>CART</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$0.7</td>
<td>$0.65</td>
<td>$0.7</td>
<td>$40.00</td>
<td>$70.7K</td>
<td>55</td>
<td>1.0K</td>
</tr>
<tr>
<td>CART</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.8</td>
<td>$3.6</td>
<td>$3.79</td>
<td>$42.00</td>
<td>$63.2K</td>
<td>1.3K</td>
<td>241</td>
</tr>
<tr>
<td>CART</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$4.7</td>
<td>$4.5</td>
<td>$4.6</td>
<td>$40.00</td>
<td>$45.9K</td>
<td>190</td>
<td>114</td>
</tr>
<tr>
<td>CART</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.1</td>
<td>$1.95</td>
<td>$2.1</td>
<td>$36.00</td>
<td>$37.3K</td>
<td>178</td>
<td>178</td>
</tr>
</tbody>
</table>

<h3>About Maplebear</h3>
Maplebear (Instacart) operates a leading grocery delivery platform in the United States and Canada. The company partners with various regional and national grocers, which offer their selection of food and other goods to customers through Instacart's ubiquitous platform. Once an item is ordered through Instacart's site, the item is picked and delivered to the customer's home by one of the platform's 600,000 shoppers, who are classified as independent contractors. Instacart earns fees based on average order value and leverages its platform's high usage to sell advertising, mainly to consumer-packaged goods companies. Instacart currently has about 8 million monthly active users (or orderers) on its platform.
After a thorough review of the options trading surrounding Maplebear, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Maplebear</h3>
<ul>
<li>Trading volume stands at 2,223,941, with CART's price down by -1.31%, positioned at $40.2.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 68 days.</li>
</ul>
<h3>What Analysts Are Saying About Maplebear</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $54.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from B of A Securities persists with their Neutral rating on Maplebear, maintaining a target price of $53. 
&#x2A; Consistent in their evaluation, an analyst from Citizens Capital Markets keeps a Market Outperform rating on Maplebear with a target price of $55. 
&#x2A; Maintaining their stance, an analyst from Stifel continues to hold a Buy rating for Maplebear, targeting a price of $57. 
&#x2A; An analyst from BMO Capital persists with their Market Perform rating on Maplebear, maintaining a target price of $49. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $56. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Maplebear with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

CART

Maplebear Options Trading: A Deep Dive into Market Sentiment

On Thursday, Amphastar Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 94 cents</a>.
Amphastar is a biopharmaceutical company focusing primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/ac44024962/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full-year-ended-dece" rel="noreferrer noopener">inhalation, and intranasal products</a>.
The company reported sales of $186.5 million, up 20% year over year, missing the consensus of $188.81 million.
Jack Zhang, Amphastar&#8217;s President and Chief Executive Officer, commented, &#8220;We are incredibly proud that in 2024, we exceeded our long-term goal of achieving&nbsp;$100 million&nbsp;in annual sales for Primatene MIST, and we look forward to continuing to grow the brand. Furthermore, BAQSIMI&nbsp;showed strong factory sales growth of 12% compared to the fourth quarter of last year. As we look ahead to 2025, we plan to continue developing and growing our proprietary pipeline.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40754258/jp-morgan-shows-most-interest-in-teva-organon-as-specialty-pharma-sector-exhibits-s" rel="noreferrer noopener">JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability</a>
Primatene MIST&nbsp;exceeded the long-term goal of&nbsp;$100 million&nbsp;in annual sales (around $29 million in the quarter), while&nbsp;BAQSIMI&nbsp;contributed&nbsp;$41.8 million&nbsp;in direct sales during the fourth quarter alone ($126.9 million&nbsp;for the full year).
JP Morgan says the company has seen some setbacks over the past several months, including a competitive approval for glucagon (~15% of Amphastar revenues) and several pipeline delays.
Analyst Ekaterina Knyazkova sees limited downside for the stock as Amphastar shares are now in the low $30s. Primatene MIST and Baqsimi continue growing, with the current valuation reflecting little value for Amphastar&#8217;s extensive R&amp;D efforts and pipeline.
JP Morgan maintains the Overweight rating for Amphastar&#8217;s stock with a <a target="_blank" href="https://www.benzinga.com/quote/AMPH/analyst-ratings" rel="noreferrer noopener">price target of $45.</a>
Price Action: AMPH stock is down 8.35% at $28.86 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44046550/nayax-acquires-uppay-in-53m-deal-adding-25000-self-service-points-to-its-brazilian-network" target="_blank" rel="noreferrer noopener">Nayax Expands In Brazil With UPPay Acquisition, Taps Into New Payment Points</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Analyst Color

Guidance

Reiteration

AMPH

Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds

Citigroup analyst Ben Gerlinger maintains First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Buy and raises the price target from $24 to $25.

Citigroup Maintains Buy on First Horizon, Raises Price Target to $25

Citigroup analyst Filippo Falorni maintains Monster Beverage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) with a Buy and raises the price target from $62 to $64.

MNST

Citigroup Maintains Buy on Monster Beverage, Raises Price Target to $64

State Street Global Advisors and Apollo Global Management have made headlines with the launch of their private credit ETF, the SPDR SSGA Apollo IG Public &amp; Private Credit ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIV#NYSE">PRIV</a>). This ETF, which began trading on Feb. 27, marks a significant development in the convergence of private credit and public markets.
PRIV is designed to offer investors risk-adjusted returns and steady income, with a net expense ratio of 70 basis points. The fund has been in the spotlight since State Street and Apollo <a href="https://www.benzinga.com/markets/equities/24/09/40815656/apollo-and-state-street-team-up-to-unlock-private-market-fortunes-details">announced their partnership in September</a> last year, drawing interest from advisors eager to gain exposure to private credit via an ETF structure.
The fund allocates at least 80% of its net assets to investment-grade debt, while also incorporating a crucial private equity element. This private credit exposure is facilitated through Apollo's expertise, giving investors a unique way to tap into this market segment. In addition, PRIV allocates its funds in a diverse mix of fixed-income securities and has the flexibility to invest up to 20% in high-yield bonds.
Also Read: <a href="https://www.benzinga.com/news/financing/25/02/44023523/apollo-global-management-in-talks-to-lead-35-billion-financing-for-metas-ai-data-centers">Apollo Global Management In Talks To Lead $35 Billion Financing For Meta&#8217;s AI Data Centers</a>
SEC Scrutiny Amid Strong Demand
PRIV's debut comes as investor appetite for private credit surges. PRIV saw solid first-day interest, attracting net inflows of $1.2 million. However, the U.S. Securities and Exchange Commission (SEC) has raised <a href="https://www.sec.gov/Archives/edgar/data/1516212/000000000025002259/filename1.pdf">concerns </a>regarding the ETF's liquidity, naming conventions and valuation compliance. A letter sent by the SEC flagged issues with the fund's transparency and questioned why certain details in a key agreement between State Street and Apollo were heavily redacted.
State Street has acknowledged the SEC's concerns and expressed plans to respond accordingly. Apollo, meanwhile, has maintained that the ETF's strong trading debut, highlighting confidence in its strategy of bridging private and public markets.
To meet SEC guidelines, the fund will cap illiquid investments at 15%, though its private credit exposure is <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001516212/000119312525035495/d865902d485bpos.htm#fact-identifier-27">expected </a>to range from 10% to 35%. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/44048438/trump-restaurant-in-the-metaverse-presidents-trademark-shows-fans-could-wear-virtual-maga-">Trump Restaurant In The Metaverse? President&#8217;s Trademark Shows Fans Could Wear Virtual MAGA Hats There Soon</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

SSGA Active Trust SPDR SSGA Apollo IG Public & Private Credit ETF

PRIV

New ETF PRIV Bridges Private And Public Credit, Draws Investor Interest And SEC Concerns

WIIM

Oil is lower amid volatility on US tariff concerns. The commodity gained after Trump and Zelensky cancelled a planned press conference but has since reversed.

Citigroup analyst Tyler Radke maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Neutral and lowers the price target from $350 to $335.

Citigroup Maintains Neutral on Salesforce, Lowers Price Target to $335

First Trust introduced the First Trust Small Cap Buy Write Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTKI#NYSE">FTKI</a>). This <a href="https://www.benzinga.com/etfs">actively managed fund</a> aims to provide investors with a steady income stream while navigating the volatility of small-cap stocks.
FTKI employs a buy-write strategy, combining stock ownership with the sale of call options on the Russell 2000 Index. This strategy helps generate income while capping potential upside gains. The fund's structure caters to investors looking for both small-cap exposure and an additional income source.
Among the fund's initial holdings are FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAIM#NASDAQ">FTAIM</a>), Insmed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), and Argan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGX#NYSE">NGX</a>) with nearly equal weightings. These stocks reflect the fund's focus on diverse small-cap opportunities. Industrials, Financials, and Health Care currently hold the top sectoral allocations in the fund, at 20.42%, 18.09%, and 13.39% of the total assets under management, respectively.
Also Read: <a href="https://www.benzinga.com/trading-ideas/25/02/43975122/matrix-asset-advisors-unveils-new-active-etf-for-value-driven-investors">Matrix Asset Advisors Unveils New Active ETF For Value-Driven Investors</a>
The expense ratio carried by this ETF is 0.85%.
With this launch, First Trust&#8217;s ETF lineup includes 169 U.S.-listed funds managing a total of $160 billion in assets. As investors continue seeking innovative ways to balance growth and income, FTKI presents an intriguing option in the evolving ETF landscape.
&#8220;Income-oriented investors have traditionally shied away from small-cap stocks due to their lower dividend yields,&#8221; said Ryan Issakainen, senior vice-president and ETF Strategist at First Trust. &#8220;FTKI offers a way to gain access to this segment while potentially generating a relatively high level of income.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/02/44050929/teslas-sharp-drop-sends-shockwaves-through-these-etfs">Tesla&#8217;s Sharp Drop Sends Shockwaves Through These ETFs</a></li>
</ul>
Photo: Shutterstock

FTAIM

First Trust Exchange-Traded Fund VI First Trust Small Cap BuyWrite Income ETF

FTKI

INSM

Nuveen Insured Massachusetts Tax-Free Advantage Municipal Fund

First Trust's New Small-Cap ETF Aims To Combine Growth With Income

Citigroup analyst David Lebowitz maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Neutral and raises the price target from $12 to $14.

NTLA

Citigroup Maintains Neutral on Intellia Therapeutics, Raises Price Target to $14

Citigroup analyst Ygal Arounian maintains Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) with a Neutral and lowers the price target from $7.8 to $5.9.

Citigroup Maintains Neutral on Outbrain, Lowers Price Target to $5.9

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Canaccord Genuity analyst Joseph Vafi downgraded the rating for ICF International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICFI#NASDAQ">ICFI</a>) from Buy to Hold and lowered the price target from $200 to $100. ICF International shares closed at $99.97 on Thursday. <a href="https://www.benzinga.com/quote/ICFI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Colin Sebastian downgraded Playtika Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTK#NASDAQ">PLTK</a>) from Outperform to Neutral and lowered the price target from $9 to $6. Playtika shares closed at $5.70 on Thursday. <a href="https://www.benzinga.com/quote/PLTK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Adam Angelov downgraded Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) from Neutral to Underperform and lowered the price target from $105 to $90. Logitech International shares closed at $101.21 on Thursday. <a href="https://www.benzinga.com/quote/LOGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst George Hill downgraded Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) from Hold to Sell and lowered the price target from $11 to $9. Walgreens shares closed at $11.23 on Wednesday. <a href="https://www.benzinga.com/quote/WBA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Tom Curran downgraded Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) from Buy to Neutral. Array Technologies shares closed at $6.55 on Thursday. <a href="https://www.benzinga.com/quote/ARRY/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/44018351/top-3-utilities-stocks-you-may-want-to-dump-in-february">Top 3 Utilities Stocks You May Want To Dump In February</a></li>
</ul>

Downgrades

ARRY

ICFI

LOGI

PLTK

This Walgreens Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

Citigroup analyst Jason Gursky maintains Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Buy and lowers the price target from $35 to $33.

RKLB

Citigroup Maintains Buy on Rocket Lab USA, Lowers Price Target to $33

Archer Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) stock gained Friday after <a target="_blank" href="https://www.benzinga.com/quote/ACHR/analyst-ratings" rel="noreferrer noopener">Wall Street analysts rerated</a> it after its fourth-quarter report Thursday.
The <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/44028619/archer-aviation-stock-falls-on-q4-earnings-the-details" rel="noreferrer noopener">company reported a</a> fourth-quarter loss of $1.42 per share, missing analyst estimates for a loss of $1.24 per share.
Archer Aviation said its quarterly spending stayed within the guided range and remained close to flat for the second straight quarter.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/02/44018937/c3-ai-sees-stronger-revenue-but-analyst-concerned-over-profitability-and-scale" rel="noreferrer noopener">C3.ai Sees Stronger Revenue But Analyst Concerned Over Profitability And Scale</a>
The company ended the period with $834.5 million in cash and equivalents.
JPMorgan analyst Bill Peterson maintained a Neutral rating on Archer Aviation with a price target of $9.
The timing of FAA certification is unclear and most likely even further delayed. The Launch Edition program could help monetize aircraft even before FAA certification in jurisdictions willing to move faster. The analyst noted the piloted flight as a significant de-risking event. 
The Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) contract manufacturing deal will close this quarter. The cash burn will likely rise in 2025 to support certification, with potential offsets from customers and partners.
Like the Joby Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) report, the analyst noted this quarter was mixed, with further evidence of delays on the FAA front.
Peterson noted the Launch Edition program could at least lessen cash burn.
The analyst expects of the ~10 aircraft Archer will produce from Covington this year, more than half will be allocated for Launch deliveries, with the remainder reserved for the test fleet.
Peterson noted the U.S. Department of Defense&#8217;s application for the hybrid VTOL opportunity is more extensive and prioritized, coupled with Agility Prime&#8217;s declining role.
Peterson also noted that the first piloted flight in the U.S. is a long-awaited milestone that institutional investors need to see to be more comfortable with Archer&#8217;s technology.
Peterson projected a first-quarter loss of $0.21 per share.
ACHR Price Action: Archer Aviation stock is up 8.08% at $8.56 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/emerging-markets/25/02/44017638/chinas-baidu-and-catl-team-up-to-build-next-gen-driverless-evs-integrating-advanced-battery-and-chassis-tech" target="_blank" rel="noreferrer noopener">China&#8217;s Baidu And CATL Team Up To Build Next-Gen Driverless EVs, Integrating Advanced Battery And Chassis Tech</a></li>
</ul>
Courtesy of Archer Aviation, Inc.

ACHR

JOBY

STLA

Archer Aviation's Stellantis Deal, Launch Program Strengthen Growth Prospects, FAA Certification Looms

Citigroup analyst Ygal Arounian maintains Opendoor Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) with a Neutral and lowers the price target from $1.8 to $1.4.

OPEN

Citigroup Maintains Neutral on Opendoor Technologies, Lowers Price Target to $1.4

LNSR

LENSAR shares are trading higher after Lake Street maintained a Buy rating on the stock and raised its price target from $12 to $16.

Across the recent three months, 4 analysts have shared their insights on GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $6.56, along with a high estimate of $8.00 and a low estimate of $6.00. Observing a downward trend, the current average is 12.53% lower than the prior average price target of $7.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1740769262_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of GoodRx Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.25</td>
<td>$7.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to GoodRx Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of GoodRx Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of GoodRx Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into GoodRx Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GDRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GoodRx Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know GoodRx Holdings Better</h2>
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
<h3>GoodRx Holdings's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining GoodRx Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.5% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: GoodRx Holdings's net margin excels beyond industry benchmarks, reaching 2.03%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): GoodRx Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of 0.58%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): GoodRx Holdings's ROA excels beyond industry benchmarks, reaching 0.28%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.78, GoodRx Holdings faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GDRX

The Analyst Verdict: GoodRx Holdings In The Eyes Of 4 Experts

Press Releases

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Management

Zevra Therapeutics Announces Organizational Changes

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

Zevra to Participate at Upcoming Investor Conferences

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

Contracts

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Zevra Launches New Disease State Awareness Campaign, 'Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Comments

Zevra Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga